In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Reata Pharmaceuticals Inc (RETA) (NASDAQ:RETA) reported that Huff James Warren has picked up 930,068 of common stock as of 2016-12-07.
The acquisition brings the aggregate amount owned by Huff James Warren to a total of 930,068 representing a 9.6% stake in the company.
For those not familiar with the company, Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
A glance at Reata Pharmaceuticals Inc (NASDAQ: RETA)’s key stats reveals a current market capitalization of $509.73 million based on $8.31 million shares outstanding and a price at last close of $24.26 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-08-22, Nielsen picked up 1780 shares at a purchase price of $17.00. This brings their total holding to 1780 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Reata Pharmaceuticals Inc (NASDAQ: RETA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
